Clinical trial / 2023
In patients with Alzheimer's disease, 12 weeks of spirulina intake improved MMSE scores, hs-CRP, and glucose homeostasis parameters compared to placebo.
Sixty patients with Alzheimer's disease were randomized to receive either 500 mg/day spirulina twice daily or placebo for 12 weeks. Compared with placebo, spirulina significantly improved MMSE score (+0.30 ± 0.99 vs. -0.38 ± 1.06, p = 0.01). Spirulina also reduced hs-CRP (-0.17 ± 0.29 vs. +0.05 ± 0.27 mg/L, p = 0.006), fasting glucose (-4.56 ± 7.93 vs. +0.80 ± 2.95 mg/dL, p = 0.002), insulin (-0.37 ± 0.62 vs. +0.12 ± 0.40 μIU/mL, p = 0.001), and insulin resistance (-0.08 ± 0.13 vs. 0.03 ± 0.08, p = 0.001), while increasing insulin sensitivity (+0.003 ± 0.005 vs. -0.001 ± 0.003, p = 0.003).
- Study type
- Randomized, double-blind, controlled clinical trial
- Who was studied
- 60 subjects with Alzheimer's disease
- What was measured
- Mini-mental state examination (MMSE) score and metabolic markers
THE PAPER
The effects of spirulina intake on clinical and metabolic parameters in Alzheimer's disease: A randomized, double-blind, controlled trial.
Tamtaji OR, Heidari-Soureshjani R, Asemi Z, Kouchaki E. Phytother Res, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.